Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.
Type:
Application
Filed:
September 17, 2021
Publication date:
November 16, 2023
Applicants:
NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
Inventors:
Laurent REBER, Pierre BRUHNS, Eva CONDE GARCIA, Marija BACKOVIC, Vincent SERRA, Géraldine GROUARD-VOGEL, Romain BERTRAND
Abstract: The invention relates to a method and a system for the plasma treatment of successive substrates comprising one or more steel products in which the substrates are transported, one after another, through at least one plasma treatment zone, characterized in that the electric power for generating the plasma in the treatment zone is varied according to the area of the substrate is present in this treatment zone when the substrate is running through this zone.
Abstract: An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.
Type:
Application
Filed:
May 29, 2019
Publication date:
July 8, 2021
Applicants:
NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
Inventors:
Géraldine GROUARD-VOGEL, Eva CONDE GARCÌA, Romain BERTRAND, Noémie CAILLOT, Laurent REBER, Pierre BRUHNS, Vincent SERRA
Abstract: A prosthetic valve comprises a self-expanding frame which includes a self-expanding atrial skirt that forms a flanged region, a self-expanding ventricular skirt, and a first self-expanding tab coupled with the ventricular skirt. A receptacle for receiving a valve leaflet is formed by the area bounded by an outer surface of the atrial skirt, an outer surface of the ventricular skirt, and an inner surface of the first tab. The receptacle has a window for receiving the valve leaflet that is defined by a gap between an edge of the flange and a tip of the first tab. The gap is maximized when the tip of the first tab is unconstrained and a base of the first tab is at least partially constrained. The gap is minimized when the tip of the first tab and its base are unconstrained.
Type:
Grant
Filed:
December 14, 2016
Date of Patent:
July 30, 2019
Assignee:
Neovac Tiara Inc.
Inventors:
Randy Matthew Lane, Colin A. Nyuli, Alexei J. Marko
Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
Type:
Grant
Filed:
April 4, 2012
Date of Patent:
June 12, 2018
Assignee:
NEOVACS
Inventors:
Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
Abstract: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.
Abstract: The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFN?, IL-4, TNF? and TGF?, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an amount ranging from 0.006 ng to 0.05 ng of the said cytokine in vitro.
Type:
Grant
Filed:
September 15, 2004
Date of Patent:
March 25, 2014
Assignee:
Neovacs
Inventors:
Bernard Bizzini, Helene Le Buanec, Daniel Zagury
Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
Type:
Application
Filed:
April 4, 2012
Publication date:
January 23, 2014
Applicant:
NEOVACS
Inventors:
Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
Abstract: A stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject, characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.
Abstract: An immunogenic product includes TNF? coupled with KLH, wherein the TNF? is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the immunogenic product and methods for preparing the immunogenic product are also described.
Type:
Application
Filed:
December 8, 2010
Publication date:
June 14, 2012
Applicant:
NEOVACS
Inventors:
Géraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIÈRE
Abstract: The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released in the extracellular (stromal) environment by cancer or stromal cells of malignant tumors, and a pharmaceutically acceptable carrier for inducing a systemic or mucosal immune response with secretory formation of class IgC or IgA neutralizing antibodies directed against the native factor, or which is derived from such a factor and the use of said immunogen to obtain a medicine for use as anticancer drug.
Type:
Grant
Filed:
April 13, 2007
Date of Patent:
January 24, 2012
Assignee:
Neovacs
Inventors:
Jean Francois Zagury, Bernard Bizzini, Helene Le Buanec, Daniel Zagury
Abstract: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.
Abstract: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.
Abstract: The present invention concerns a novel method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNF? and a carrier protein, the method steps of which are disclosed in the specification.
Abstract: An immumogenic polypeptide for inducing antibodies that neutralize the immunosuppressive and/or angiogenic activity of an E7 protein from Papillomavirus, wherein said immunogenic polypeptide consists of an E7 protein from Papillomavirus that has been inactivated so as to eliminate at least 70% of the immunosuppressive and/or angiogenic activity of the non-inactivated E7 protein. The inactivation is effected by physical and/or chemical treatments and/or by modification of the amino acid sequence of the polypeptide.
Abstract: The present invention concerns a novel method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNF? and a carrier protein, the method steps of which are disclosed in the specification.
Abstract: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.
Abstract: The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released in the extracellular (stromal) environment by cancer or stromal cells of malignant tumors, and a pharmaceutically acceptable carrier for inducing a systemic or mucosal immune response with secretory formation of class IgC or IgA neutralizing antibodies directed against the native factor, or which is derived from such a factor and the use of said immunogen to obtain a medicine for use as anticancer drug.
Type:
Application
Filed:
April 13, 2007
Publication date:
February 7, 2008
Applicant:
NEOVACS
Inventors:
Jean-Francois ZAGURY, Bernard BIZZINI, Helene LE BUANEC, Daniel ZAGURY
Abstract: The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in: i. the 1-19 amino acid sequence of sequence SEQ ID No. 3; ii. an amino acid sequence possessing (a) the substitution of at least one amino acid, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3 or (b) the deletion of at least four consecutive amino acids, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3; and iii. the 30-98 amino acid sequence of sequence SEQ ID No 3.
Type:
Grant
Filed:
April 4, 2003
Date of Patent:
January 1, 2008
Assignee:
Neovacs
Inventors:
Daniel Zagury, Hélène Le Buanec, Bernard Bizzini
Abstract: The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFN?, IL-4, TNF? and TGF?, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an amount ranging from 0.006 ng to 0.05 ng of the said cytokine in vitro.
Type:
Application
Filed:
September 15, 2004
Publication date:
August 30, 2007
Applicant:
NEOVACS
Inventors:
Bernard Bizzini, Helene Le Buanec, Daniel Zagury